Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 30;42(11):746-760.
doi: 10.1002/jcc.26494. Epub 2021 Feb 14.

Toward efficient generation, correction, and properties control of unique drug-like structures

Affiliations

Toward efficient generation, correction, and properties control of unique drug-like structures

Maksym Druchok et al. J Comput Chem. .

Abstract

Efficient design and screening of the novel molecules is a major challenge in drug and material design. This paper focuses on a multi-stage pipeline, in which several deep neural network models are combined to map discrete molecular representations into continuous vector space to later generate from it new molecular structures with desired properties. Here, the Attention-based Sequence-to-Sequence model is added to "spellcheck" and correct generated structures, while the oversampling in the continuous space allows generating candidate structures with desired distribution for properties and molecular descriptors, even for a small reference datasets. We further use computer simulation to validate the desired properties in the numerical experiment. With the focus on the drug design, such a pipeline allows generating novel structures with a control of Synthetic Accessibility Score and a series of metrics that assess the drug-likeliness. Our code is available at https://github.com/SoftServeInc/novel-molecule-generation.

Keywords: autoencoder; deep neural networks; machine learning; molecular design.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. M. Dickson, J. P. Gagnon, Nat. Rev. Drug Discov. 2004, 3, 417. https://doi.org/10.1038/nrd1382.
    1. A. Jahan, M. Y. Ismail, S. M. Sapuan, F. Mustapha, Mater. Des. 2010, 31, 696. https://doi.org/10.1016/j.matdes.2009.08.013.
    1. A. Schuhmacher, O. Gassmann, M. Hinder, J. Transl. Med. 2016, 14, 105. https://doi.org/10.1186/s12967-016-0838-4.
    1. J. C. Babiarz, in FDA Regulatory affairs. A guide for prescription drugs, medical devices, and biologics, 2nd ed. (Eds: D. J. Pisano, D. S. Mantus), Informa Healthcare, New York 2008; Chapter 1, p. 34.
    1. E. Petrova, Innovation and Marketing in the Pharmaceutical Industry; (Eds: M. Ding, et al), International Series in Quantitative Marketing 20, Springer-Verlag, New York 2014. DOI: https://doi.org/10.1007/978-1-4614-7801-0

Substances

LinkOut - more resources